| scholarly article | Q13442814 |
| P2093 | author name string | Turesson I | |
| Sundan A | |||
| Waage A | |||
| Dahl IM | |||
| Seidel C | |||
| Hjorth M | |||
| Abildgaard N | |||
| Borset M | |||
| P433 | issue | 2 | |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | 388-392 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Serum syndecan-1: a new independent prognostic marker in multiple myeloma | |
| P478 | volume | 95 |
| Q37032148 | A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma |
| Q38260615 | A cytoplasmic C-terminal fragment of Syndecan-1 is generated by sequential proteolysis and antagonizes Syndecan-1 dependent lung tumor cell migration |
| Q33581409 | A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells |
| Q61061795 | A transmembrane C-terminal fragment of syndecan-1 is generated by the metalloproteinase ADAM17 and promotes lung epithelial tumor cell migration and lung metastasis formation |
| Q35759368 | An update of novel therapeutic approaches for multiple myeloma |
| Q36737006 | Bone disease in multiple myeloma |
| Q34155848 | Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis |
| Q89128650 | CARs and other T cell therapies for MM: The clinical experience |
| Q47927555 | CD138 mediates selection of mature plasma cells by regulating their survival |
| Q36452712 | Chemical synthesis of a heparan sulfate glycopeptide: syndecan-1. |
| Q42021140 | Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse |
| Q35070558 | Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia |
| Q37771370 | Development of target-specific treatments in multiple myeloma |
| Q34039967 | Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. |
| Q28394538 | Differential expression of syndecan-1 mediates cationic nanoparticle toxicity in undifferentiated versus differentiated normal human bronchial epithelial cells |
| Q33400076 | Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients |
| Q63583282 | Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations |
| Q39431959 | Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan |
| Q35879934 | Heparan sulfate chains of syndecan-1 regulate ectodomain shedding |
| Q34441253 | Heparan sulfate proteoglycans and cancer. |
| Q38312824 | Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma |
| Q36499443 | Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma |
| Q36973696 | Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma |
| Q33754644 | Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis |
| Q37499263 | Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins |
| Q37371146 | Heparanase: busy at the cell surface |
| Q34258579 | IL-8 as a urinary biomarker for the detection of bladder cancer |
| Q36919158 | Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applications |
| Q38868904 | Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma |
| Q38528036 | Interactions of signaling proteins, growth factors and other proteins with heparan sulfate: mechanisms and mysteries |
| Q30244089 | Mechanisms of heparanase inhibitors in cancer therapy |
| Q35196655 | Molecular and genetic prognostic factors of prostate cancer |
| Q37950202 | Molecular functions of syndecan-1 in disease. |
| Q47318797 | Molecular targets and signaling pathways regulated by nuclear translocation of syndecan-1. |
| Q37415946 | Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. |
| Q37379726 | Non-anticoagulant heparins and inhibition of cancer |
| Q38014834 | Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions |
| Q36071884 | Novel therapeutic targets in the brain tumor microenvironment |
| Q53334967 | Prognostic significance of syndecan-1 expression in squamous cell carcinoma of the tonsil. |
| Q58914769 | Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance |
| Q36787608 | Proteoglycans in cancer biology, tumour microenvironment and angiogenesis |
| Q34398151 | Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis |
| Q35830856 | Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies |
| Q35551894 | Shed syndecan-2 enhances tumorigenic activities of colon cancer cells |
| Q36245624 | Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model |
| Q53354177 | Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia. |
| Q36977717 | Soluble cadherins as cancer biomarkers |
| Q34316917 | Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma? |
| Q34179480 | Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia |
| Q34316858 | Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study |
| Q89184746 | Soluble syndecans: biomarkers for diseases and therapeutic options |
| Q57494295 | Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations |
| Q26784262 | Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication |
| Q42064478 | Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. |
| Q37008599 | Syndecan-1: a dynamic regulator of the myeloma microenvironment |
| Q38189392 | Syndecans as modulators and potential pharmacological targets in cancer progression |
| Q38054541 | Syndecans in cartilage breakdown and synovial inflammation |
| Q39973608 | Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. |
| Q38078480 | The heparanase/syndecan-1 axis in cancer: mechanisms and therapies |
| Q44585463 | The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma. |
| Q38176008 | The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors |
| Q35990705 | The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy |
| Q38196396 | Topographical changes in extracellular matrix: Activation of TLR4 signaling and solid tumor progression |
| Q42038842 | Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma |
Search more.